Tavaborole – a treatment for onychomycosis of the toenails

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2016-07-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17512433.2016.1206467PMID 27347905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.

  2016cited by this paper
• Onychomycosis: Strategies to Minimize Recurrence.

  2016cited by this paper
• Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis

  2016cited by this paper
• Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis

  2016cited by this paper
• In Vitro Nail Penetration of Tavaborole Topical Solution, 5%, Through Nail Polish on Ex Vivo Human Fingernails.

  2015cited by this paper
• Spotlight on tavaborole for the treatment of onychomycosis

  2015cited by this paper
• Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape.

  2015cited by this paper
• In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.

  2015cited by this paper
• Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.

  2015cited by this paper
• Onychomycosis in Israel: epidemiological aspects

  2015cited by this paper
• Mechanism of Quinolone Action and Resistance

  2014cited by this paper
• Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream.

  2014cited by this paper
• Diagnosis and management of tinea infections.

  2014cited by this paper
• The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

  2014cited by this paper
• The prevalence of onychomycosis in the global population – A literature study

  2014cited by this paper
• Oral Terbinafine and Itraconazole Treatments against Dermatophytes Appear Not to Favor the Establishment of Fusarium spp. in Nail

  2014cited by this paper
• Tavaborole, a Novel Boron-Containing Small Molecule for the Topical Treatment of Onychomycosis, Is Noncarcinogenic in 2-Year Carcinogenicity Studies

  2014cited by this paper
• Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis

  2014cited by this paper
• The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

  2014cited by this paper
• Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis

  2014cited by this paper
• The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

  2014cited by this paper
• Molecular determination of mixed infections of dermatophytes and nondermatophyte molds in individuals with onychomycosis.

  2014cited by this paper
• Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults

  2014cited by this paper
• Efinaconazole: First Global Approval

  2013cited by this paper
• Onychomycosis Does Not Always Require Systemic Treatment for Cure: A Trial Using Topical Therapy

  2013cited by this paper
• Therapies for the treatment of onychomycosis.

  2013cited by this paper
• The epidemiology, etiology, and pathophysiology of onychomycosis.

  2013cited by this paper
• Mechanism of Action of Efinaconazole, a Novel Triazole Antifungal Agent

  2013cited by this paper
• The impact of nail disorders on quality of life.

  2013cited by this paper
• Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.

  2013cited by this paper
• Onychomycosis: burden of disease and the role of topical antifungal treatment.

  2013cited by this paper
• Onchomycosis: an overview.

  2013cited by this paper
• Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.

  2012cited by this paper
• New therapeutic options for onychomycosis

  2012cited by this paper
• Update: medical treatment of onychomycosis

  2012cited by this paper
• Toenail onychomycosis: an important global disease burden

  2010cited by this paper
• Enhancing the nail permeability of topically applied drugs

  2008cited by this paper
• In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.

  2007cited by this paper
• Recent progress on the topical therapy of onychomycosis

  2007cited by this paper
• Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh.

  2007cited by this paper
• Guidance for Industry and FDA Staff

  2006cited by this paper
• Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.

  2006cited by this paper
• Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria

  2006cited by this paper
• Identification of borinic esters as inhibitors of bacterial cell growth and bacterial methyltransferases, CcrM and MenH.

  2005cited by this paper
• Treatment options – development of consensus guidelines

  2005cited by this paper
• Risk factors associated with onychomycosis

  2004cited by this paper
• Treatment of Onychomycosis: Pros and Cons of Antifungal Agents

  2004cited by this paper
• Common Fungal Infections of the Feet in Patients with Diabetes Mellitus

  2004cited by this paper
• Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence.

  2004cited by this paper
• Treatment Failures and Relapses in Onychomycosis: A Stubborn Clinical Problem

  2003cited by this paper
• Onychomycosis in clinical practice: factors contributing to recurrence.

  2003cited by this paper
• Guidelines for treatment of onychomycosis

  2003cited by this paper
• Drug delivery to the nail following topical application.

  2002cited by this paper
• The diagnosis of onychomycosis in a geriatric population: a study of 450 cases in South Florida.

  2001cited by this paper
• Ciclopirox nail lacquer solution 8% in the 21st century.

  2000cited by this paper
• Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.

  2000cited by this paper
• Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients.

  2000cited by this paper
• Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey

  1998cited by this paper
• Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up

  1998cited by this paper
• Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.

  1998cited by this paper
• Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion.

  1994cited by this paper
• Mechanisms of action of systemic antifungal agents.

  1993cited by this paper
• Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use.

  1992cited by this paper

• Zn2+-Driven Tavaborole-Adenosine Hydrogel: A Strategy for Enhanced Solubility, Sustained Release, and Antifungal Efficacy.

  2026cites this paper
• Recent advanced in C–H borylation using BX3 with different directing group auxiliary

  2025cites this paper
• Recent Advancements in the Diversification and Applications of Boron-Containing Compounds in Medicinal Chemistry

  2025cites this paper
• Flow Process for Production of Crisaborole Using Organolithium Chemistry with Control over Impurity Formation

  2025cites this paper
• ADVANCES IN ANTIFUNGAL THERAPY FOR ONCHOMYCOSIS: A FOCUS ON EMERGING AGENTS AND TECHNOLOGIES

  2025cites this paper
• Malassezia spp. carbonic anhydrases.

  2025cites this paper
• Novel pleuromutilin derivatives conjugated with phenyl-sulfide and boron-containing moieties as potent antibacterial agents against antibiotic-resistant bacteria.

  2024cites this paper
• New Formulation–Microporation Combination Approaches to Delivering Ciclopirox across Human Nails

  2024cites this paper
• Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial

  2024cites this paper
• A recent review on transungual drug delivery system

  2024cites this paper
• A comparative study of boron-containing and boron-omitted capsaicinoids

  2023cites this paper
• Tavaborole-Induced Inhibition of the Aminoacyl-tRNA Biosynthesis Pathway against Botrytis cinerea Contributes to Disease Control and Fruit Quality Preservation.

  2022cites this paper
• Novel and Investigational Treatments for Onychomycosis

  2022cites this paper
• Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series

  2021cites this paper
• Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi

  2021cites this paper
• Oxidative degradation profile studies of Tavaborole by a validated stability indicating RP-UPLC method: Isolation and characterization of novel degradant using 2D-NMR and HRMS.

  2021cites this paper
• In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum

  2021cites this paper
• What is the elephant in the room when considering new therapies for fungal diseases?

  2021cites this paper
• What’s New in Pediatric Nail Disorders?

  2021cites this paper
• Recent developments in the medicinal chemistry of single boron atom-containing compounds

  2021cites this paper
• Molecular targets for antifungals in amino acid and protein biosynthetic pathways

  2021influential citation
• A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination In Vitro Susceptibilities of Isolated Fungal Strains to Conventional and New Antifungals

  2021cites this paper
• Benzoxaboroles: New emerging and versatile scaffold with a plethora of pharmacological activities

  2021cites this paper
• Legacy and Innovative Treatment: Projected Modalities for Antimicrobial Intervention

  2020cites this paper
• Onychomycosis in children – review on treatment and management strategies

  2020cites this paper
• Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis

  2018cites this paper
• Clinical and veterinary trypanocidal benzoxaboroles target CPSF3

  2018cites this paper
• Benzoboroxoles: Synthesis and applications in medicinal chemistry

  2018cites this paper
• Semisynthesis and Biological Evaluation of Xanthone Amphiphilics as Selective, Highly Potent Antifungal Agents to Combat Fungal Resistance.

  2017cites this paper
• Antifungals

  2017cites this paper
• Trans-ungual Delivery of AR-12, a Novel Antifungal Drug

  2017cites this paper